Interferon Regulatory Factor-1 (IRF1) activates autophagy to promote liver ischemia/reperfusion injury by inhibiting β-catenin in mice.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
11
2019
accepted:
27
07
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
22
12
2020
Statut:
epublish
Résumé
Autophagy is an important factor in liver ischemia-reperfusion injury. In the current study we investigate the function of interferon regulatory factor-1 (IRF1) in regulating autophagy to promote hepatic ischemia reperfusion injury (IR). The high expression of IRF1 during hepatic IR exhibited increased liver damage and was associated with activation of autophagy shown by Western blot markers, as well as immunofluorescent staining for autophagosomes. These effects were diminished by IRF1 deficiency in IRF1 knock out (KO) mice. Moreover, the autophagy inhibitor 3-MA decreased IR-induced liver necrosis and markedly abrogated the rise in liver injury tests (AST/ALT). β-catenin expression decreased during liver IR and was increased in the IRF1 KO mice. Immunoprecipitation assay showed the binding between IRF1 and β-catenin. Overexpression of IRF1 induced autophagy and also inhibited the expression of β-catenin. β-catenin inhibitor increased autophagy while β-catenin agonist suppressed autophagy in primary mouse hepatocytes. These results indicate that IRF1 induced autophagy aggravates hepatic IR injury in part by inhibiting β-catenin and suggests that targeting IRF1 may be an effective strategy in reducing hepatic IR injury.
Identifiants
pubmed: 33137133
doi: 10.1371/journal.pone.0239119
pii: PONE-D-19-31287
pmc: PMC7605671
doi:
Substances chimiques
CTNNB1 protein, mouse
0
Interferon Regulatory Factor-1
0
Irf1 protein, mouse
0
beta Catenin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0239119Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK120531
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA113263
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Annu Rev Pathol. 2018 Jan 24;13:351-378
pubmed: 29125798
Gastroenterology. 2011 Aug;141(2):707-18, 718.e1-5
pubmed: 21679710
J Pathol. 2000 Feb;190(3):255-66
pubmed: 10685060
J Immunol. 2015 Jun 15;194(12):6045-56
pubmed: 25964490
Hepatology. 2010 May;51(5):1692-701
pubmed: 20131404
Surgery. 2009 Aug;146(2):181-9
pubmed: 19628072
Cancer Lett. 2012 Jan 28;314(2):213-22
pubmed: 22056812
J Immunol. 2005 Dec 1;175(11):7661-8
pubmed: 16301676
Transplant Proc. 2005 May;37(4):1653-6
pubmed: 15919422
Am J Physiol Gastrointest Liver Physiol. 2018 Dec 1;315(6):G991-G1002
pubmed: 30307739
Oncogene. 2004 Feb 5;23(5):1125-35
pubmed: 14762441
Transplant Proc. 2010 Dec;42(10):3977-80
pubmed: 21168604
Am J Transplant. 2011 Aug;11(8):1563-9
pubmed: 21668640
Exp Mol Pathol. 2003 Apr;74(2):86-93
pubmed: 12710939
Cell. 2008 Jan 11;132(1):27-42
pubmed: 18191218
Shock. 2011 Mar;35(3):293-301
pubmed: 20856174
Biol Reprod. 2016 Feb;94(2):32
pubmed: 26674566
Br J Cancer. 2018 Jan;118(1):62-71
pubmed: 29112686
Am J Surg. 2001 Feb;181(2):160-6
pubmed: 11425059
Cancer Res. 2015 Mar 15;75(6):1046-55
pubmed: 25576084
Cell Death Dis. 2013 Jun 27;4:e694
pubmed: 23807223
Cell Physiol Biochem. 2018;48(1):328-338
pubmed: 30016764
Hepatology. 2018 Mar;67(3):1056-1070
pubmed: 29059701
Sci Rep. 2017 Mar 07;7:43684
pubmed: 28266555
Cell Physiol Biochem. 2014;33(1):23-36
pubmed: 24401531
Am J Physiol Lung Cell Mol Physiol. 2017 Feb 1;312(2):L186-L195
pubmed: 27941077
World J Gastroenterol. 2017 Dec 28;23(48):8443-8451
pubmed: 29358854
J Hepatol. 2019 Jan;70(1):108-117
pubmed: 30287339
Mediators Inflamm. 2013;2013:461536
pubmed: 24453420
J Immunol. 2003 Jan 15;170(2):997-1001
pubmed: 12517966
Hepatology. 2013 Mar;57(3):1203-14
pubmed: 23081841